预防婴儿呼吸道合胞病毒感染的人源化单克隆抗体临床研究最新进展  

Recent advances in clinical research of humanized monoclonal antibodies against respiratory syncytial virus infection in infants

作　　者：谢正德 郑跃杰[2] 卢根[3] 薛凤霞 申昆玲 Xie Zhengde;Zheng Yuejie;Lu Gen;Xue Fengxia;Shen Kunling(Beijing Key Laboratory of Pediatric Respiratory Infection Diseases,Key Laboratory of Major Diseases in Children,Ministry of Education,National Clinical Research Center for Respiratory Diseases,Research Unit of Critical Infection in Children,Chinese Academy of Medical Sciences,2019RU016,Laboratory of Infection and Virology,Beijing Pediatric Research Institute,Beijing Children′s Hospital,Capital Medical University,National Center for Children′s Health,Beijing 100045,China;Department of Respiratory,Shenzhen Children′s Hospital,Shenzhen 518038,China;Department of Respiratory,Guangzhou Women and Children′s Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Respiratory,Beijing Children′s Hospital,Capital Medical University,National Clinical Research Center for Respiratory Disease,National Center for Children′s Health,Beijing 100045,China)

机构地区：[1]国家儿童医学中心,首都医科大学附属北京儿童医院,北京市儿科研究所,中国医学科学院儿童危重感染诊治创新单元,国家呼吸系统疾病临床医学研究中心,儿科重大疾病研究教育部重点实验室,儿童呼吸道感染性疾病研究北京市重点实验室,北京100045 [2]深圳市儿童医院呼吸科,深圳518038 [3]广州医科大学附属广州市妇女儿童医疗中心呼吸科,广州510623 [4]国家儿童医学中心,国家呼吸系统疾病临床医学研究中心,首都医科大学附属北京儿童医院呼吸科,北京100045

出　　处：《中华实用儿科临床杂志》2022年第7期481-485,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：呼吸道合胞病毒(respiratory syncytial virus,RSV)是导致1岁以下婴儿罹患下呼吸道感染(lower respiratory tract infection,LRTI)的首要病毒病原,严重危害婴儿健康。大部分(约80%)RSV感染的LRTI住院婴儿是足月出生的健康婴儿。目前国内RSV预防和治疗领域,尚无有效药物或预防手段。新型全人源长效单克隆抗体Nirsevimab具有较强中和RSV能力、超长半衰期,通过单剂注射,即可为所有婴儿在第1个RSV流行季提供快速直接的免疫保护,预示预防婴儿RSV感染新时代即将来临。Respiratory syncytial virus(RSV)is the leading cause of lower respiratory tract infection(LRTI)and hospitalizations in infants under 1 year of age,seriously jeopardizing infants′health.Most hospitalizations(up to 80%)due to RSV-LRTI occur in otherwise healthy infants born at term.At present,no effective treatment and preventative measure against RSV is available domestically.Passive immunization with fully human long-acting monoclonal antibody Nirsevimab offers immediate protection for all infants experiencing their first RSV season with one shot,thus ushering in a new era of prevention of RSV infection among infants.

关 键 词：呼吸道合胞病毒 婴儿 长效单克隆抗体 Nirsevimab 

分 类 号：R725.6[医药卫生—儿科]